AIM ImmunoTech Inc. AIM
an immuno-pharma company headquartered in Ocala, Florida, and focused on the research and development of therapeutics to treat multiple
types of cancers, viral diseases and immune-deficiency disorders for which there are inadequate or unmet therapies. We have established
a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of nucleic acids and natural interferon
to enhance the natural antiviral defense system of the human body, and to aid the development of therapeutic products for the treatment
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $88.0K | $170.0K | $202.0K | $141.0K | $135.0K | $163.0K | $140.0K | $367.0K | $437.0K | $92.0K |
| R&D | $3.9M | $6.2M | $10.9M | $7.0M | $7.7M | $5.7M | $4.7M | $4.8M | $4.1M | $5.1M |
| SG&A | $7.7M | $13.7M | $21.1M | $13.1M | $8.7M | $8.7M | $7.0M | $6.2M | $6.6M | $7.7M |
| Total operating expenses | $11.8M | $19.9M | $32.1M | $20.1M | $19.0M | $15.3M | $12.6M | $11.9M | $11.9M | $13.9M |
| Operating income | -$11.7M | -$19.8M | -$31.9M | -$19.9M | -$18.8M | -$15.2M | -$12.4M | -$11.5M | -$11.4M | -$13.8M |
| Interest expense | $812.0K | $585.0K | — | — | $67.0K | $672.0K | $427.0K | $201.0K | — | — |
| Pre-tax income | -$14.0M | — | — | — | — | — | — | — | — | — |
| Net income | -$14.0M | -$17.3M | -$29.0M | -$19.4M | -$19.1M | -$14.4M | -$9.4M | -$9.8M | -$8.3M | -$7.5M |
| EPS, basic | -8.62 | -30.92 | -0.60 | -0.40 | -0.40 | — | — | — | — | — |
| EPS, diluted | -8.62 | -30.92 | -0.60 | -0.40 | -0.40 | -0.45 | -2.58 | -9.77 | -0.29 | -0.34 |
| Shares, diluted (wtd. avg.) | $1.6M | $560.2K | $48.6M | $48.0M | — | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $3.0M | $1.7M | $5.4M | $27.1M | $32.1M | $38.5M | $1.5M | $299.0K | $1.4M | $2.4M |
| Short-term investments | $62.0K | $2.3M | $7.6M | $7.1M | $16.2M | $501.0K | $7.3M | — | — | — |
| Receivables | $7.0K | — | $1.2M | $1.7M | — | $34.0K | $44.0K | $235.0K | $24.0K | — |
| Total current assets | $3.3M | $4.2M | $14.6M | $36.3M | $50.2M | $40.3M | $10.4M | $3.8M | $3.5M | $6.9M |
| Property, plant and equipment | $71.0K | $108.0K | $127.0K | $195.0K | $4.0M | $6.5M | $7.1M | $7.8M | $8.6M | $9.5M |
| Other intangibles | $1.7M | $2.6M | $2.3M | $1.9M | $2.0M | $1.5M | $1.2M | $911.0K | $858.0K | $872.0K |
| Total assets | $5.8M | $8.6M | $19.4M | $40.5M | $57.7M | $64.6M | $20.8M | $13.8M | $14.2M | $18.9M |
| Accounts payable | $1.6M | $6.4M | $6.4M | $377.0K | $198.0K | $383.0K | $472.0K | $680.0K | $741.0K | $887.0K |
| Short-term debt | $3.5M | $2.3M | — | — | — | $230.0K | $214.0K | $199.0K | — | — |
| Total current liabilities | $6.2M | $9.5M | $8.7M | $1.4M | $673.0K | $1.1M | $1.1M | $5.3M | $2.7M | $2.4M |
| Long-term debt | $927.0K | $2.8M | — | — | — | $1.9M | $2.1M | $2.3M | — | — |
| Total liabilities | $15.6M | $9.9M | $9.1M | $2.0M | — | — | — | — | — | — |
| Retained earnings | -$440.8M | -$426.8M | -$409.5M | -$380.5M | -$361.1M | -$342.0M | -$327.6M | -$318.6M | -$308.8M | -$300.5M |
| Total equity | -$9.8M | -$1.3M | $10.2M | $38.5M | $56.9M | $61.3M | $13.4M | $5.6M | $8.7M | $15.5M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$11.0M | -$14.9M | -$21.3M | -$16.1M | -$14.0M | -$10.4M | -$9.1M | -$10.6M | -$7.9M | -$7.4M |
| Depreciation and amortisation | $37.0K | $37.0K | $39.0K | $38.0K | $659.0K | $665.0K | $735.0K | $856.0K | $948.0K | $1.1M |
| Stock-based compensation | $60.0K | $686.0K | $243.0K | $954.0K | $1.6M | $1.0M | $853.0K | $929.0K | $571.0K | $52.0K |
| Capital expenditure | — | $18.0K | — | $86.0K | $41.0K | $22.0K | $68.0K | $51.0K | $20.0K | $160.0K |
| Investing cash flow | $1.9M | $4.7M | -$832.0K | $11.0M | -$631.0K | -$9.2M | -$6.1M | $92.0K | $2.7M | $2.9M |
| Financing cash flow | $10.4M | $6.4M | $485.0K | $80.0K | $8.2M | $56.6M | $16.4M | $9.4M | $4.2M | $4.8M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-013301.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $236.38B | 30.7x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $187.23B | 22.3x | 2.4% |
| MRNA | Moderna, Inc. | $58.11B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $45.01B | — | — |
| BIIB | BIOGEN INC. | $32.60B | 25.1x | 2.2% |
| SCNI | Scinai Immunotherapeutics Ltd. | $25.80B | — | 99.2% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $15.82B | 33.3x | 21.4% |
| EXEL | EXELIXIS, INC. | $14.62B | 21.2x | 7.0% |